uniQure N.V. Income Tax Expense
uniQure N.V. (QURE) reported Income Tax Expense of $488.00 thousand for the 3-month period ending 2026-03-31, per its 10-Q filed 2026-05-05.
Financial Statements › Expense Statement › Income Tax
us-gaap:IncomeTaxExpenseBenefit · last filed 2026-05-05
- uniQure N.V. income tax expense (benefit) for the quarter ending 2026-03-31 was $488.00K, a 1.61% decline year-over-year.
- uniQure N.V. income tax expense (benefit) for the quarter ending 2025-12-31 was -$3.92M, a 557.48% decline year-over-year.
- uniQure N.V. income tax expense (benefit) for the quarter ending 2025-09-30 was $8.63M.
- uniQure N.V. income tax expense (benefit) for the quarter ending 2025-06-30 was $425.00K, a 55.17% decline year-over-year.
- uniQure N.V. income tax expense (benefit) for fiscal 2025 was $5.63M, a 131.82% increase from fiscal 2024.
- uniQure N.V. income tax expense (benefit) for fiscal 2024 was $2.43M, a 26.44% increase from fiscal 2023.
- uniQure N.V. income tax expense (benefit) for fiscal 2023 was $1.92M.
- uniQure N.V. income tax expense (benefit) for fiscal 2022 was -$1.47M, a 145.69% decline from fiscal 2021.
| Period end | Income Tax Expense (Benefit) 3 month | Income Tax Expense (Benefit) 6 month | Income Tax Expense (Benefit) 9 month | Income Tax Expense (Benefit) 12 month |
|---|---|---|---|---|
| 2026-03-31 | $488.00K 10-Q · filed 2026-05-05 | -$3.43M derived: sum of 2 quarters · filed 2026-05-05 | $5.20M derived: sum of 3 quarters · filed 2026-05-05 | $5.62M derived: sum of 4 quarters · filed 2026-05-05 |
| 2025-12-31 | -$3.92M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | $4.71M derived: sum of 2 quarters · filed 2026-03-02 | $5.13M derived: sum of 3 quarters · filed 2026-03-02 | $5.63M 10-K · filed 2026-03-02 |
| 2025-09-30 | $8.63M 10-Q · filed 2025-11-10 | $9.05M derived: sum of 2 quarters · filed 2025-11-10 | $9.55M 10-Q · filed 2025-11-10 | $10.40M derived: sum of 4 quarters · filed 2026-05-05 |
| 2025-06-30 | $425.00K 10-Q · filed 2025-07-29 | $921.00K 10-Q · filed 2025-07-29 | $1.78M derived: sum of 3 quarters · filed 2026-05-05 | $1.75M derived: sum of 4 quarters · filed 2026-05-05 |
| 2025-03-31 | $496.00K 10-Q · filed 2026-05-05 | $1.35M derived: sum of 2 quarters · filed 2026-05-05 | $1.32M derived: sum of 3 quarters · filed 2026-05-05 | $2.27M derived: sum of 4 quarters · filed 2026-05-05 |
| 2024-12-31 | $856.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | $825.00K derived: sum of 2 quarters · filed 2026-03-02 | $1.77M derived: sum of 3 quarters · filed 2026-03-02 | $2.43M 10-K · filed 2026-03-02 |
| 2024-09-30 | -$31.00K 10-Q · filed 2025-11-10 | $917.00K derived: sum of 2 quarters · filed 2025-11-10 | $1.57M 10-Q · filed 2025-11-10 | $4.61M derived: sum of 4 quarters · filed 2026-03-02 |
| 2024-06-30 | $948.00K 10-Q · filed 2025-07-29 | $1.60M 10-Q · filed 2025-07-29 | $4.64M derived: sum of 3 quarters · filed 2026-03-02 | $4.57M derived: sum of 4 quarters · filed 2026-03-02 |
| 2024-03-31 | $656.00K 10-Q · filed 2025-05-09 | $3.69M derived: sum of 2 quarters · filed 2026-03-02 | $3.62M derived: sum of 3 quarters · filed 2026-03-02 | $3.78M derived: sum of 4 quarters · filed 2026-03-02 |
| 2023-12-31 | $3.03M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | $2.96M derived: sum of 2 quarters · filed 2026-03-02 | $3.13M derived: sum of 3 quarters · filed 2026-03-02 | $1.92M 10-K · filed 2026-03-02 |
| 2023-09-30 | -$69.00K 10-Q · filed 2024-11-05 | $94.00K derived: sum of 2 quarters · filed 2024-11-05 | -$1.11M 10-Q · filed 2024-11-05 | -$1.32M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-06-30 | $163.00K 10-Q · filed 2024-08-01 | -$1.04M 10-Q · filed 2024-08-01 | -$1.25M derived: sum of 3 quarters · filed 2025-02-27 | -$1.58M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-03-31 | -$1.21M 10-Q · filed 2024-05-07 | -$1.41M derived: sum of 2 quarters · filed 2025-02-27 | -$1.74M derived: sum of 3 quarters · filed 2025-02-27 | -$2.06M derived: sum of 4 quarters · filed 2025-02-27 |
| 2022-12-31 | -$207.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | -$536.00K derived: sum of 2 quarters · filed 2025-02-27 | -$854.00K derived: sum of 3 quarters · filed 2025-02-27 | -$1.47M 10-K · filed 2025-02-27 |
| 2022-09-30 | -$329.00K 10-Q · filed 2023-11-07 | -$647.00K derived: sum of 2 quarters · filed 2023-11-07 | -$1.26M 10-Q · filed 2023-11-07 | -$1.61M derived: sum of 4 quarters · filed 2024-02-28 |
| 2022-06-30 | -$318.00K 10-Q · filed 2023-08-01 | -$934.00K 10-Q · filed 2023-08-01 | -$1.28M derived: sum of 3 quarters · filed 2024-02-28 | -$1.19M derived: sum of 4 quarters · filed 2024-02-28 |
| 2022-03-31 | -$616.00K 10-Q · filed 2023-05-09 | -$959.00K derived: sum of 2 quarters · filed 2024-02-28 | -$870.00K derived: sum of 3 quarters · filed 2024-02-28 | $2.39M derived: sum of 4 quarters · filed 2024-02-28 |
| 2021-12-31 | -$343.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-28 | -$254.00K derived: sum of 2 quarters · filed 2024-02-28 | $3.00M derived: sum of 3 quarters · filed 2024-02-28 | $3.22M 10-K · filed 2024-02-28 |
| 2021-09-30 | $89.00K 10-Q · filed 2022-11-02 | $3.35M derived: sum of 2 quarters · filed 2022-11-02 | $3.56M 10-Q · filed 2022-11-02 | -$12.86M derived: sum of 4 quarters · filed 2023-02-27 |
| 2021-06-30 | $3.26M 10-Q · filed 2022-08-08 | $3.47M 10-Q · filed 2022-08-08 | -$12.95M derived: sum of 3 quarters · filed 2023-02-27 | -$12.95M derived: sum of 4 quarters · filed 2023-02-27 |
| 2021-03-31 | $213.00K 10-Q · filed 2022-05-02 | -$16.21M derived: sum of 2 quarters · filed 2023-02-27 | -$16.21M derived: sum of 3 quarters · filed 2023-02-27 | -$16.21M derived: sum of 4 quarters · filed 2023-02-27 |
| 2020-12-31 | -$16.42M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-27 | -$16.42M derived: sum of 2 quarters · filed 2023-02-27 | -$16.42M derived: sum of 3 quarters · filed 2023-02-27 | -$16.42M 10-K · filed 2023-02-27 |
| 2020-09-30 | $0.00 10-Q · filed 2021-10-25 | $0.00 derived: sum of 2 quarters · filed 2021-10-25 | $0.00 10-Q · filed 2021-10-25 | |
| 2020-06-30 | $0.00 10-Q · filed 2021-07-26 | $0.00 10-Q · filed 2021-07-26 | ||
| 2018-12-31 | -$6.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-01 | -$38.00K derived: sum of 2 quarters · filed 2021-03-01 | $323.00K derived: sum of 3 quarters · filed 2021-03-01 | $231.00K 10-K · filed 2021-03-01 |
| 2018-09-30 | -$32.00K 10-Q · filed 2019-10-28 | $329.00K derived: sum of 2 quarters · filed 2019-10-28 | $237.00K 10-Q · filed 2019-10-28 | $316.00K derived: sum of 4 quarters · filed 2020-03-02 |
| 2018-06-30 | $361.00K 10-Q · filed 2019-07-29 | $269.00K 10-Q · filed 2019-07-29 | $348.00K derived: sum of 3 quarters · filed 2020-03-02 | $70.00K derived: sum of 4 quarters · filed 2020-03-02 |
| 2018-03-31 | -$92.00K 10-Q · filed 2019-04-29 | -$13.00K derived: sum of 2 quarters · filed 2020-03-02 | -$291.00K derived: sum of 3 quarters · filed 2020-03-02 | |
| 2017-12-31 | $79.00K derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-02 | -$199.00K derived: sum of 2 quarters · filed 2020-03-02 | -$199.00K 10-K · filed 2020-03-02 | |
| 2017-09-30 | -$278.00K 10-Q · filed 2018-11-06 | -$278.00K 10-Q · filed 2018-11-06 | ||
| 2016-12-31 | $744.00K derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-28 | $921.00K derived: sum of 2 quarters · filed 2019-02-28 | $588.00K derived: sum of 3 quarters · filed 2019-02-28 | $1.15M 10-K · filed 2019-02-28 |
| 2016-09-30 | $177.00K 10-Q · filed 2017-11-01 | -$156.00K derived: sum of 2 quarters · filed 2017-11-01 | $401.00K 10-Q · filed 2017-11-01 | |
| 2016-06-30 | -$333.00K 10-Q · filed 2017-08-08 | $224.00K 10-Q · filed 2017-08-08 | ||
| 2016-03-31 | $557.00K 10-Q · filed 2017-05-09 | |||
| 2015-12-31 | -$1.18M 10-K · filed 2018-03-14 | |||
| 2014-12-31 | -$535.00K 10-K · filed 2017-03-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Zai Lab Ltd (ZLAB) | $2.241B | -113.34 |